biotech

Why This Anthrax Vaccine Study Is Getting a New Cash Injection

Altimmune Inc. (NASDAQ: ALT) shares jumped on Wednesday after the company announced that the Biomedical Advanced Research and Development Authority (BARDA) is modifying its existing anthrax vaccine development contract with ...
Read Full Story »

4 Biotechs Making Major Moves on Tuesday

Tuesday was a breakout day for a few biotech companies that saw either huge gains or massive losses. With the markets holding near all-time highs, these companies could move the ...
Read Full Story »

Endo Benefits Greatly From Potential Ohio Opioid Case Settlement

The opioid crisis has been devastating to many families and communities throughout America. After years of making major profits from the sale of opioids, many drug companies have come under ...
Read Full Story »

Meet the FDA’s Newest Fast Tracked Zika Virus Treatment

Moderna, Inc. (NASDAQ: MRNA) shares jumped late on Monday after the firm announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for its investigational Zika ...
Read Full Story »

Why the FDA Is a Little Slow on This Jet Lag Study

Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) shares dropped early to begin the week after the firm announced that it received a Complete Response Letter (CRL) from the U.S. Food and Drug ...
Read Full Story »

Good News for Stem Cell Transplants

Akari Therapeutics PLC (NASDAQ: AKTX) shares jumped on Wednesday after the firm announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for its stem cell ...
Read Full Story »

Breakthrough Gastrointestinal Tumor Therapy Reaches New Milestone

Deciphera Pharmaceuticals Inc. (NASDAQ: DCPH) shares nearly doubled on Tuesday after the firm announced top-line results from its late-stage trial treating patients with gastrointestinal stromal tumors (GIST). Specifically, this data ...
Read Full Story »

Dividend Investors Have Reasons to Look to Big Biotech Over Big Pharma Ahead

Over the past three decades, the unlimited investing potential of biotechnology was all about growth. Companies could grow from nothing to see untold billions of dollars selling cures and treatments ...
Read Full Story »

8 Biotechs Being Choked by Short Sellers

This has been a hard year for biotech. It seems that both Democrats and Republicans are wanting to target drug prices, and fears of universal health care in the years ...
Read Full Story »

Short Sellers Make a Move on Big Biotechs

The short interest data are out for the most recent settlement date, July 31. Generally speaking, companies within the biotech industry are considered a riskier group of stocks, with big ...
Read Full Story »

Is Amarin’s Cardio Trial in Trouble?

Amarin Corp. PLC (NASDAQ: AMRN) shares dropped on Friday after the firm announced that it received notice from the U.S. Food and Drug Administration (FDA). According to the notice, the ...
Read Full Story »

Oil & Gas, Apparel, Pharma Vying for S&P 500’s Worst Group of 2019

The stock market has experienced yet another 5% correction after hitting all-time highs just in July. What really stands out for 2019, particularly if you just followed the emotions of ...
Read Full Story »

Revolutionary Peanut Allergy Treatment Is One Step Closer

Shares of DBV Technologies S.A. (NASDAQ: DBVT) shot up on Thursday after the company announced the submission of its Biologics License Application (BLA) to the U.S. Food and Drug Administration ...
Read Full Story »

What These Late-Stage Obesity Studies Could Mean for the Future of Rhythm Pharmaceuticals

Rhythm Pharmaceuticals Inc. (NASDAQ: RYTM) shares jumped on Wednesday after the company announced positive results from two of its late-stage obesity clinical trials. Specifically, the data come from two Phase ...
Read Full Story »

Insulin Delivery Growth Driving Insulet Higher and Higher

Aren't politicians going after drug prices and just about any costs tied to health care that they can get their hands and minds around? That may be the case during ...
Read Full Story »